Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.58 |
| ▸ | HTR2B | P41595 | 11/20 | 0.58 |
| ▸ | HTR2A | P28223 | 9/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5917497 | 0.73 | HTR2C (1.00) | HTR2CHTR2BHTR2AKCNH2 | |
| SCHEMBL5917500 | 0.73 | HTR2C (1.00) | HTR2CHTR2BHTR2AKCNH2 | |
| SCHEMBL4995439 | 0.72 | HTR2C (0.63) | HTR2CHTR2BHTR2AKCNH2NOS1 | |
| SCHEMBL5871727 | 0.72 | HTR2A (0.43) | HTR2CHTR2BHTR2A | |
| SCHEMBL28106897 | 0.71 | KDR (0.42) | HTR2CHTR2BHTR2AKCNH2MEN1 | |
| SCHEMBL5871243 | 0.70 | HTR2A (0.37) | HTR2CHTR2BHTR2AKCNH2TP53 | |
| SCHEMBL23212021 | 0.69 | HTR2C (0.80) | HTR2CHTR2BHTR2AKCNH2NOS1 | |
| SCHEMBL2709111 | 0.67 | HTR2C (0.77) | HTR2CHTR2BHTR2AKCNH2MEN1 | |
| SCHEMBL21274020 | 0.67 | PIK3R1 (0.48) | HTR2CHTR2BHTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL3947175 | 0.66 | HTR2C (0.75) | HTR2CHTR2BHTR2AKCNH2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | HTR2C 222/4885HTR2B 91/4885HTR2A 209/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | HTR2C 107/4885HTR2B 45/4885HTR2A 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.